Eton Pharmaceutcials Inc (ETON)

$63.43 +1.70 (2.75%)
Market Cap 1.69B
Revenue (ttm) 79.95M
Net Income (ttm) -4.60M
EPS (ttm) N/A
PE Ratio 154.89
Forward PE 87.85
Profit Margin -5.75%
Debt to Equity Ratio 0.60
Volume 872,400
Avg Vol 540,744
Day's Range N/A - N/A
Shares Out 27.39M
Stochastic %K 99%
Beta 0.86
Analysts Strong Sell
Price Target $61.30

Company Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyros...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 847 787 7361
Address:
21925 W. Field Parkway, Suite 235, Deer Park, United States
Finnish_boy
Finnish_boy Aug. 19 at 11:14 AM
$HROW $ETON is very well managed company but not undervalued anymore. Time to lock 1,400% profits. Nailed it. HROW will outperfrom ETON very heavily for the next 1-2 years.
0 · Reply
KarinSparrow145
KarinSparrow145 Aug. 19 at 9:07 AM
$ETON $ARQQ $DUOL $BETR Eton Pharmaceuticals advances specialty medicines, Arqit remains focused on quantum-safe cybersecurity, Duolingo benefits from language-learning engagement and subscriptions, and BETR remains highly speculative. I'm watching prescription growth, cybersecurity adoption, subscriber growth, and funding.
0 · Reply
OracleofOntario
OracleofOntario Aug. 18 at 11:30 PM
$ETON This will be a $3B company soon enough
0 · Reply
jacksparo
jacksparo Aug. 18 at 8:35 PM
$ETON If I just count only this one with its more than 1500% since alerted should be enough as a success rate for the last two years. Yet some came from no where blaming me about other stocks that they their selves didn’t do well in trading them. The market designed to reward you if you understand it’s game and to punish you if you think every time you will hit the button you will make money!
1 · Reply
prat1703
prat1703 Aug. 18 at 8:26 PM
$ETON : Hello everyone, this ticker caught my eye today - what's the sentiment here, FOMO pump? Definitely not a short squeeze so this is organic buying.
0 · Reply
maniha
maniha Aug. 18 at 10:35 AM
$ETON odds they stock split sometime soon?
1 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Aug. 18 at 7:29 AM
$ETON Eton Pharmaceuticals, Inc. (NASDAQ: ETON) delivered a massive earnings beat, 99% product sales growth and stronger 2026 guidance. See what sent ETON stock soaring after its latest quarterly report. https://globalmarketbulletin.com/is-eton-pharmaceuticals-eton-a-hidden-healthcare-growth-stock-worth-watching/
1 · Reply
Zardiw
Zardiw Aug. 17 at 11:08 PM
$WETO - #DDAmanda Chart. Worth a trade or stay away? Others on the radar: $SST $DAAQ $ETON Best Stock Finder: https://DDAmanda.com
0 · Reply
Zardiw
Zardiw Aug. 17 at 10:34 PM
$WETO - #DDAmanda Chart. Worth a trade or stay away? Others on the radar: $SST $DAAQ $ETON Best Stock Finder: https://DDAmanda.com
0 · Reply
Biorocksme
Biorocksme Aug. 17 at 8:57 PM
$ETON hot stock. CFO Matthews picked a winner post death Iterum $ITRM When will you ask for cash ?
0 · Reply
Latest News on ETON
Eton Pharmaceuticals participates in a conference call with Craig-Hallum

2026-08-17T15:15:36.000Z - 1 day ago

Eton Pharmaceuticals participates in a conference call with Craig-Hallum

Eton Pharmaceuticals reports Q2 non-GAAP EPS 43c, consensus 19c

2026-08-16T14:08:39.000Z - 2 days ago

Eton Pharmaceuticals reports Q2 non-GAAP EPS 43c, consensus 19c

Eton Pharmaceuticals sees FY26 revenue exceeding $145M consensus $121.32M

2026-08-16T14:07:57.000Z - 2 days ago

Eton Pharmaceuticals sees FY26 revenue exceeding $145M consensus $121.32M

Eton Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright

2026-08-16T13:50:51.000Z - 2 days ago

Eton Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright

Eton Pharmaceuticals price target raised to $70 from $40 at B. Riley

2026-08-16T13:21:19.000Z - 2 days ago

Eton Pharmaceuticals price target raised to $70 from $40 at B. Riley

Eton Pharmaceuticals price target raised to $68 from $60 at Canaccord

2026-08-16T13:18:48.000Z - 2 days ago

Eton Pharmaceuticals price target raised to $68 from $60 at Canaccord

Eton Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Eton Pharmaceuticals Earnings Call Transcript: Q2 2026

Eton Pharmaceuticals Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Eton Pharmaceuticals Earnings release: Q2 2026

Eton Pharmaceuticals Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Eton Pharmaceuticals Quarterly report: Q2 2026

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 4:05 PM EDT - 5 days ago

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eton Pharmaceuticals price target raised to $65 from $57 at H.C. Wainwright

2026-08-11T10:15:49.000Z - 8 days ago

Eton Pharmaceuticals price target raised to $65 from $57 at H.C. Wainwright

Eton Pharmaceuticals licenses U.S. rights to ASN-001 from Auson

2026-08-05T11:31:54.000Z - 14 days ago

Eton Pharmaceuticals licenses U.S. rights to ASN-001 from Auson

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Aug 5, 2026, 6:50 AM EDT - 14 days ago

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Aug 3, 2026, 6:50 AM EDT - 16 days ago

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Eton reports results from new formulation of Khindivi study

2026-07-29T11:20:53.000Z - 21 days ago

Eton reports results from new formulation of Khindivi study

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Jul 29, 2026, 6:50 AM EDT - 21 days ago

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals price target raised to $62 from $40 at Craig-Hallum

2026-07-28T13:20:29.000Z - 21 days ago

Eton Pharmaceuticals price target raised to $62 from $40 at Craig-Hallum

Eton Pharmaceuticals initiated with a Buy at Canaccord

2026-07-17T09:40:14.000Z - 4 weeks ago

Eton Pharmaceuticals initiated with a Buy at Canaccord

Eton Pharmaceuticals initiated with a Buy at Canaccord

2026-07-16T20:16:10.000Z - 4 weeks ago

Eton Pharmaceuticals initiated with a Buy at Canaccord

Eton Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:55 AM EDT - 2 months ago

Eton Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Eton Pharmaceuticals enters supply, distribution agreement for Impavido

2026-05-19T20:40:09.000Z - 3 months ago

Eton Pharmaceuticals enters supply, distribution agreement for Impavido

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

May 19, 2026, 4:30 PM EDT - 3 months ago

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals price target raised to $57 from $52 at H.C. Wainwright

2026-05-15T14:27:03.000Z - 3 months ago

Eton Pharmaceuticals price target raised to $57 from $52 at H.C. Wainwright

Eton Pharmaceuticals Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Eton Pharmaceuticals Earnings Call Transcript: Q1 2026

Eton Pharmaceuticals Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Eton Pharmaceuticals Earnings release: Q1 2026

Eton Pharmaceuticals Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Eton Pharmaceuticals Quarterly report: Q1 2026

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

May 14, 2026, 4:05 PM EDT - 3 months ago

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026, 4:30 PM EDT - 3 months ago

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Eton Pharmaceuticals announces relaunch of Hemangeol

2026-05-01T11:06:48.000Z - 3 months ago

Eton Pharmaceuticals announces relaunch of Hemangeol

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

May 1, 2026, 6:50 AM EDT - 3 months ago

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

Eton Pharmaceuticals says first patient dosed in study of ET-700

2026-04-27T11:01:30.000Z - 4 months ago

Eton Pharmaceuticals says first patient dosed in study of ET-700

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Apr 27, 2026, 6:50 AM EDT - 4 months ago

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Eton Pharmaceuticals Proxy statement: Proxy filing

Eton Pharmaceuticals appoints Judith Matthews as CFO

2026-04-16T11:31:33.000Z - 4 months ago

Eton Pharmaceuticals appoints Judith Matthews as CFO

Eton Pharmaceuticals Announces CFO Succession Plan

Apr 16, 2026, 6:50 AM EDT - 4 months ago

Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Eton Pharmaceuticals Earnings Call Transcript: Q4 2025

Eton Pharmaceuticals Annual report: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Eton Pharmaceuticals Annual report: Q4 2025

Eton Pharmaceuticals Earnings release: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Eton Pharmaceuticals Earnings release: Q4 2025

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026, 4:05 PM EDT - 5 months ago

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

Mar 3, 2026, 4:30 PM EST - 6 months ago

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Mar 2, 2026, 7:27 AM EST - 6 months ago

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

US FDA approves Eton Pharma's hormonal disorder drug

Feb 25, 2026, 1:51 PM EST - 6 months ago

US FDA approves Eton Pharma's hormonal disorder drug

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

Feb 25, 2026, 1:47 PM EST - 6 months ago

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Feb 20, 2026, 6:50 AM EST - 6 months ago

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Feb 2, 2026, 6:50 AM EST - 7 months ago

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

Nov 24, 2025, 4:30 PM EST - 9 months ago

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Nov 12, 2025, 4:30 PM EST - 9 months ago

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Eton Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Eton Pharmaceuticals Earnings Call Transcript: Q3 2025

Eton Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Eton Pharmaceuticals Quarterly report: Q3 2025

Eton Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Eton Pharmaceuticals Earnings release: Q3 2025

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 23, 2025, 4:30 PM EDT - 10 months ago

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

Eton Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Earnings Call Transcript: Q2 2025

Eton Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Quarterly report: Q2 2025

Eton Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Earnings release: Q2 2025

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Jul 8, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 27, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

May 28, 2025, 5:28 PM EDT - 1 year ago

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

Eton Pharmaceuticals Slides: Corporate Presentation

May 19, 2025, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Slides: Corporate Presentation

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

May 14, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Eton Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Earnings Call Transcript: Q1 2025

Eton Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Quarterly report: Q1 2025

Eton Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Earnings release: Q1 2025

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

May 13, 2025, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

Apr 28, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

Eton Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Eton Pharmaceuticals Proxy statement: Proxy Filing

Eton Pharmaceuticals Slides: Investor Presentation

Apr 4, 2025, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Slides: Investor Presentation

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Mar 25, 2025, 2:30 AM EDT - 1 year ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Eton Pharmaceuticals Transcript: Investor Day 2025

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Eton Pharmaceuticals Transcript: Investor Day 2025

Eton Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Eton Pharmaceuticals Earnings release: Q4 2024

Eton Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Eton Pharmaceuticals Annual report: Q4 2024

Eton Pharmaceuticals Slides: FY 2025

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Eton Pharmaceuticals Slides: FY 2025

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Mar 18, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Mar 14, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Mar 4, 2025, 10:00 AM EST - 1 year ago

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Mar 4, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Mar 3, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Feb 7, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Feb 6, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Jan 3, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Dec 20, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Dec 3, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Nov 25, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Eton Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals Earnings Call Transcript: Q3 2024

Eton Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals Quarterly report: Q3 2024

Eton Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals Earnings release: Q3 2024

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Oct 3, 2024, 6:30 AM EDT - 2 years ago

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 22, 2024, 4:30 PM EDT - 2 years ago

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Eton Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Eton Pharmaceuticals Earnings Call Transcript: Q2 2024

Eton Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Eton Pharmaceuticals Quarterly report: Q2 2024

Eton Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Eton Pharmaceuticals Earnings release: Q2 2024

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 2 years ago

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Finnish_boy
Finnish_boy Aug. 19 at 11:14 AM
$HROW $ETON is very well managed company but not undervalued anymore. Time to lock 1,400% profits. Nailed it. HROW will outperfrom ETON very heavily for the next 1-2 years.
0 · Reply
KarinSparrow145
KarinSparrow145 Aug. 19 at 9:07 AM
$ETON $ARQQ $DUOL $BETR Eton Pharmaceuticals advances specialty medicines, Arqit remains focused on quantum-safe cybersecurity, Duolingo benefits from language-learning engagement and subscriptions, and BETR remains highly speculative. I'm watching prescription growth, cybersecurity adoption, subscriber growth, and funding.
0 · Reply
OracleofOntario
OracleofOntario Aug. 18 at 11:30 PM
$ETON This will be a $3B company soon enough
0 · Reply
jacksparo
jacksparo Aug. 18 at 8:35 PM
$ETON If I just count only this one with its more than 1500% since alerted should be enough as a success rate for the last two years. Yet some came from no where blaming me about other stocks that they their selves didn’t do well in trading them. The market designed to reward you if you understand it’s game and to punish you if you think every time you will hit the button you will make money!
1 · Reply
prat1703
prat1703 Aug. 18 at 8:26 PM
$ETON : Hello everyone, this ticker caught my eye today - what's the sentiment here, FOMO pump? Definitely not a short squeeze so this is organic buying.
0 · Reply
maniha
maniha Aug. 18 at 10:35 AM
$ETON odds they stock split sometime soon?
1 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Aug. 18 at 7:29 AM
$ETON Eton Pharmaceuticals, Inc. (NASDAQ: ETON) delivered a massive earnings beat, 99% product sales growth and stronger 2026 guidance. See what sent ETON stock soaring after its latest quarterly report. https://globalmarketbulletin.com/is-eton-pharmaceuticals-eton-a-hidden-healthcare-growth-stock-worth-watching/
1 · Reply
Zardiw
Zardiw Aug. 17 at 11:08 PM
$WETO - #DDAmanda Chart. Worth a trade or stay away? Others on the radar: $SST $DAAQ $ETON Best Stock Finder: https://DDAmanda.com
0 · Reply
Zardiw
Zardiw Aug. 17 at 10:34 PM
$WETO - #DDAmanda Chart. Worth a trade or stay away? Others on the radar: $SST $DAAQ $ETON Best Stock Finder: https://DDAmanda.com
0 · Reply
Biorocksme
Biorocksme Aug. 17 at 8:57 PM
$ETON hot stock. CFO Matthews picked a winner post death Iterum $ITRM When will you ask for cash ?
0 · Reply
Shinta055
Shinta055 Aug. 17 at 4:58 PM
$ETON
0 · Reply
Zardiw
Zardiw Aug. 17 at 4:38 PM
Early alert paid off: $WFF up 450%. #DDAmanda Chart Previous winners: $AEYE $ETON $HHS How to find winning stocks: https://DDAmanda.com
0 · Reply
Donniechen12345
Donniechen12345 Aug. 17 at 4:22 PM
$ETON 2 day rules lol $$$$$$
0 · Reply
kshonstocks
kshonstocks Aug. 17 at 3:40 PM
$ETON 98 82 B 99 comp ibd not many that good
0 · Reply
topstockalerts
topstockalerts Aug. 17 at 2:17 PM
Top Gainers PT2 $BANL $HHS $VWAV $ETON $DAAQ
1 · Reply
StochAlpha
StochAlpha Aug. 17 at 11:48 AM
StochAlpha Daily - Top 5 Buys / Sells $ETON $AMRX $MSM $DRS $MTCH
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Aug. 16 at 5:25 PM
$BSP $ETON $MGTX $SSYS $NMAX These 5 companies delivered better-than-expected earnings, but one stood far above the rest with a massive $2.15 EPS surprise. Here are the stocks that caught Wall Street off guard this earnings season. https://globalmarketbulletin.com/5-stocks-that-beat-wall-street-at-its-own-game-in-q2-2026/
0 · Reply
herousa
herousa Aug. 16 at 2:02 AM
$ETON $CRVS That is why I joined your groups and I made big money because of that. Thank you.
0 · Reply
topstockalerts
topstockalerts Aug. 15 at 10:57 PM
Top Gainers PT2 $VWAV $ETON $DAAQ $SST $SPAI
0 · Reply
Merlintrader
Merlintrader Aug. 15 at 5:19 PM
Eton Pharmaceuticals ($ETON) Stock Hub 2026: Q2 growth, $145M guidance and the valuation test https://www.merlintrader.com/eton-pharmaceuticals-stock-hub/
0 · Reply
topstockalerts
topstockalerts Aug. 15 at 1:54 PM
Top Gainers PT2 $VWAV $ETON $DAAQ $SST $SPAI
0 · Reply
BuffettStyleInvestments
BuffettStyleInvestments Aug. 15 at 8:40 AM
$VOO $ETON $SMCI $JD VOO provides diversified S&P 500 exposure, Eton advances specialty pharmaceutical products, Super Micro benefits from AI-server demand, and JD.com remains tied to Chinese e-commerce. I'm watching market breadth, product launches, AI capex, and Chinese consumer demand.
0 · Reply